Simple and efficient method for the quantification of antiepileptic drugs in human plasma by using magnetic graphene oxide-\u03b2-cyclodextrin composite as a sorbent

The sequestration of Sr(II) and Cs(I) from aqueous solutions by magnetic graphene oxides

Simultaneous HPLC-F analysis of three recent antiepileptic drugs in human plasma

Analysis of antiepileptic drugs in human plasma using micellar electrokinetic capillary chromatography

From signal amplification to restrained background: Magnetic graphene oxide assisted homogeneous electrochemiluminescence aptasensor for highly sensitive detection of okadaic acid

The magnetic graphene oxide (MGO) composites were prepared by coprecipitation of FeCl3·6H2O and FeCl2·4H2O on graphene oxide (GO) nanosheets and characterized in detail. The Fe3O4 was uniformly deposited on the surface of GO. The synthesized MGO composites were used as a versatile adsorbent for As(V) removal from aqueous solutions. The results showed that the adsorption of As(V) on MGO is an endothermic process and the adsorption kinetic fitted the pseudo-second-order model well. The MGO composites had a good adsorption capability for As(V) removal and the adsorption isotherms were described by the Langmuir model better than by the Freundlich model. The adsorption of As(V) on MGO decreased with ascending pH due to the electrostatic interaction. In addition, the adsorption of As(V) on MGO was greatly affected by the nature and concentration of coexisting cations and anions. The presence of coexisting anions showed an inhibiting effect on As(V) adsorption, which was more efficient at low pH, whereas the presence of coexisting cations showed an enhancing effect on As(V) adsorption, which was more efficient at high pH. The results of this work indicated that the combination of the excellent adsorption capacity of GO and the magnetic properties of Fe3O4 nanoparticles is very important in drinking water treatment due to the easy magnetic separation of MGO from aqueous solutions.

To evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) in neonates with repeated electroencephalographic seizures not controlled with previous antiseizure medications (ASMs). Phase 2/3, multicenter, open-label, single-arm study (N01349/NCT03325439) in neonates with repeated electroencephalographic seizures (lasting ≥10 s) confirmed by video-electroencephalography, and inadequate seizure control with at least one ASM. A screening period (up to 36 h) was followed by a 48-h evaluation period during which patients received 0.5 mg/kg BRV twice daily (b.i.d) intravenously (IV). Patients who benefitted from BRV (investigator's opinion) could continue 0.5 mg/kg b.i.d (IV or oral solution) in an extension period. Outcomes included plasma concentrations of BRV following the first dose (primary), and incidence of treatment-emergent adverse events (TEAEs). Six patients (median [range] postnatal age: 1.5 [1.0, 6.0] days) received ≥1 dose of BRV. All six patients completed the evaluation period; two entered and completed the extension period. Overall (evaluation and extension periods), three patients received one dose of 0.5 mg/kg BRV and three received more than one dose. The median (range) duration of exposure to BRV (IV and oral solution) was 1.5 (1.0, 29.0) days (n = 6). At 0.5-1, 2-4, and 8-12 h following IV BRV administration, the GeoMean (GeoCV) plasma concentrations of BRV were 0.53 mg/L (15.40% [n = 5]), 0.50 mg/L (28.20% [n = 6]), and 0.34 mg/L (13.20% [n = 5]), respectively. Individual and population BRV PK profiles were estimated, and individual PK parameters were calculated using Bayesian feedback. The observed concentrations were consistent with the predicted PK. Three patients experienced four TEAEs, none of which were considered related to BRV. BRV plasma concentrations in neonates were consistent with data in older children receiving BRV oral solution, and with data from adults receiving a nominal IV dose of 25 mg b.i.d. BRV was well tolerated, with no drug-related TEAEs reported. Few drugs are available to treat seizures in newborn babies. Brivaracetam is approved to treat focal-onset seizures in children and adults in Europe (patients 2 years of age and older) and the United States (patients 1 month of age or older). In this study, six newborns with repeated seizures were treated with intravenous brivaracetam. The study doctors took samples of blood from the newborns and measured the levels of brivaracetam. The concentrations of brivaracetam in the newborns' blood plasma were consistent with data from studies in older children and in adults. No brivaracetam-related medical problems were reported.

Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials

Preconcentration of Pd ion in novel modified magnetic graphene oxide nanoparticles in different samples and its determination by ETAAS

The large-scale application of ionic surfactants in industrial and agricultural production has caused great harm to the environment due to by-products. In order to remove this pollutant from the environment, graphene oxide as an adsorption material has received extensive attention. However, practically, it is difficult to separate the GO from aqueous solutions, making water treatment on a large scale challenging. To allow the recycling of GO, as well as enhance its adsorption ability to remove surfactants from water, a composite of magnetic graphene oxide (MGO) and 1-dodecyl-3-methylimidazolium chloride ionic liquid (IL) was synthesized. The MGO was prepared by coprecipitation, and IL-MGO was prepared by ultrasonic impregnation. Nitrogen adsorption-desorption curves show that the specific surface area of the composite was increased by the addition of the IL, from 103.28 to 163.35 m2/g. Finally, the adsorption ability of MGO and IL-MGO for the nonionic surfactant NP10EO was investigated. The results showed that the adsorption of MGO on NP10EO fits the Langmuir isothermal model and the quasi-second-order kinetic model. In addition, the equilibrium adsorption capacity of NP10EO by MGO at 298K, 308K, and 318K can reach 87.03 mg/g, 156.25 mg/g, and 214.13 mg/g. The adsorption is an endothermic reaction that occurs spontaneously and is governed by physical adsorption. The adsorption of IL-MGO on NP10EO conforms to the Langmuir isotherm model and the quasi-second-order kinetic model. At 298K, 308K, and 318K, the equilibrium adsorption capacity of NP10EO by MGO reached 261.02 mg/g, 280.24 mg/g, and 295.03 mg/g, respectively. Compared with the two results, the incorporation of IL greatly improved the adsorption capacity of MGO to NP10EO.

Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? — A case series

Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events

IntroductionThis article aimed to assess the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal-onset seizures on specific concomitant antiseizure medications (ASMs) taken as part of their treatment regimen.MethodsThis was a post hoc analysis of pooled data from double-blind, placebo-controlled trials (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325) in patients with uncontrolled focal-onset seizures randomized to BRV (50–200 mg/day) or placebo on the most common concomitant ASMs at trial initiation.ResultsNine concomitant ASMs were analyzed: carbamazepine (CBZ), lamotrigine (LTG), valproate (VPA), oxcarbazepine (OXC), topiramate (TPM), phenytoin (PHT), lacosamide (LCM), clobazam (CLB), and phenobarbital (PHB). Reduction over placebo in focal-onset seizure frequency per 28 days with BRV ranged from 11.7% (concomitant OXC) to 33.5% (concomitant PHB). The median percentage reduction from baseline in focal-onset seizure frequency per 28 days ranged from 25.5% to 42.8% in patients on BRV (placebo 4.4–21.2%); 50% responder rates ranged from 31.9% to 44.9% in patients on BRV (placebo 11.4–25.2%). In patients on BRV, seizure freedom ranged from 1.4% (concomitant PHT) to 12.5% (concomitant LCM); seizure freedom ranged from 0% to 1.2% in patients on placebo. All efficacy endpoints analyzed were consistently numerically higher in patients on BRV versus placebo. The overall incidence of treatment-emergent adverse events (TEAEs) was generally similar across subgroups by specific concomitant ASMs in patients on BRV (range 60.8–74.5%) or placebo (range 53.8–66.7%). Drug-related TEAEs were numerically higher across all subgroups by concomitant ASM in patients on BRV (range 35.2–48.3%) versus placebo (range 23.9–37.1%). Discontinuations due to TEAEs ranged from 2.9% to 13.3% in patients on BRV and was 0–5.7% for patients taking placebo across subgroups.ConclusionBRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12325-024-02795-z.

A Parallel-Column LC–MS/MS Method for High-Throughput Analysis of Eight Antiepileptic Drugs in Clinical Therapeutic Drug Monitoring

To evaluate the influence of prior use of carbamazepine (CBZ) and other antiepileptic drugs (AEDs) with a putatively similar mechanism of action (inhibition of voltage-gated sodium channels; VGSCs) on seizure outcomes and tolerability when converting to eslicarbazepine acetate (ESL), using data pooled from 2 controlled conversion-to-ESL monotherapy trials (studies: 093-045, 093-046). Adults with treatment-resistant focal (partial-onset) seizures were randomized 2:1 to ESL 1600 or 1200 mg once daily. The primary efficacy endpoint was study exit (meeting predefined exit criteria related to worsening seizure control) versus an historical control group. Other endpoints included change in seizure frequency, responder rate, and tolerability. Endpoints were analyzed for subgroups of patients who received CBZ (or any VGSC inhibitor [VGSCi]) during baseline versus those who received other AEDs. Of 365 patients in the studies, 332 were evaluable for efficacy. The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically significant (hazard ratios were 1.49 for +CBZ vs -CBZ [P = .10] and 1.27 for +VGSCi vs. -VGSCi [P = .33]). Reductions in seizure frequency and responder rates were lower in patients who converted from CBZ or other VGSCi compared with those who converted from other AEDs. There were no notable differences in overall tolerability between subgroups, but the incidence of some adverse events (eg, dizziness, somnolence, nausea) differed between subgroups and/or between treatment periods. Baseline use of CBZ or other major putative VGSC inhibitors did not appear to significantly increase the risk of study exit due to worsening seizure control, or to increase the frequency of side effects when converting to ESL monotherapy. However, bigger improvements in efficacy may be possible in patients converting to ESL monotherapy from an AED regimen that does not include a VGSC inhibitor.

Aedes-borne diseases are of worldwide concern due to the lack of effective medicine and vaccination. Frequent use of chemical intervention has developed insecticide resistance in mosquitoes and posed health risks to humans and the environment, necessitating an effective and safer intervention. Graphene Oxide (GO) is an efficient material that can absorb pesticide particles and release pesticide macromolecules in a controlled manner. With the proposition that magnetic graphene oxide (MGO)-based nanoformulations can be an eco-safe and effective material for pesticide conjugation, the present study synthesized these nanoformulations conjugated with a pyrethroid, deltamethrin (DL) through chemical co-precipitation method. The formulations were validated using biophysical techniques and investigated for their efficacy against Aedes aegypti. The X-ray diffraction (XRD) pattern of nanocomposites showed six intense diffraction peaks of Fe3O4 particles, X-ray photoelectron spectroscopy (XPS) displayed the C1s, O1s, and Fe2p photoelectron lines in the MGO nanocomposite's spectra, while Field Emission Scanning Electron Microscopy (FESEM) revealed the small size and uniformity of Fe3O4 nanoparticles on the GO surface. The individual MGO and DL, as well as MGO-DL binary combinations (1:1, 1:2, and 1:3) imparted significant larval toxicity, demonstrating 30%, 50%, and 85% CTC (Co-toxicity coefficient), respectively. High corresponding Synergistic factor (SF) values indicated significant synergism increasing with the rise in deltamethrin proportion. The MGO-DL combinations also increased irritancy and flight response in adults, the notable synergistic effects imparted by the 1:3 combination. The effective actions of MGO-DL nanoformulations against mosquitoes suggest their possible use for mosquito management as a safer and more operative intervention.